Bausch Health Companies (BHC) Total Non-Current Liabilities (2009 - 2026)
Bausch Health Companies (BHC) reported Total Non-Current Liabilities of $24.8 billion for Q1 2026, down 4.18% on a YoY basis from $25.9 billion in Q1 2025, and down 1.5% sequentially from $25.2 billion in Q4 2025.
Bausch Health Companies (BHC) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Total Non-Current Liabilities data on file, last reported at $24.8 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 4.18% year-over-year to $24.8 billion; the trailing twelve-month figure through Mar 2026 stood at $24.8 billion (down 4.18% YoY), and the FY2025 full-year result was $25.2 billion, down 3.58% from the prior year.
- Total Non-Current Liabilities fell to $24.8 billion in Q1 2026, from $25.2 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $28.7 billion in Q1 2022 to a low of $24.5 billion in Q2 2023.
- A 5-year average of $25.9 billion and a median of $26.0 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Peak annual rise in Total Non-Current Liabilities reached 7.98% in 2023, while the deepest fall reached 14.41% in 2023.
- Tracing BHC's Total Non-Current Liabilities over 5 years: stood at $24.7 billion in 2022, then increased by 7.98% to $26.7 billion in 2023, then decreased by 1.97% to $26.1 billion in 2024, then slipped by 3.58% to $25.2 billion in 2025, then retreated by 1.5% to $24.8 billion in 2026.
- Business Quant data shows BHC's Total Non-Current Liabilities at $24.8 billion in Q1 2026, $25.2 billion in Q4 2025, and $25.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | 24.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.82 Bn |
| Dec 31, 2025 | 25.20 Bn |
| Sep 30, 2025 | 25.63 Bn |
| Jun 30, 2025 | 26.24 Bn |
| Mar 31, 2025 | 25.90 Bn |
| Dec 31, 2024 | 26.13 Bn |
| Sep 30, 2024 | 25.98 Bn |
| Jun 30, 2024 | 25.98 Bn |
| Mar 31, 2024 | 26.34 Bn |
| Dec 31, 2023 | 26.66 Bn |
| Sep 30, 2023 | 26.58 Bn |
| Jun 30, 2023 | 24.49 Bn |
| Mar 31, 2023 | 24.55 Bn |
| Dec 31, 2022 | 24.69 Bn |
| Sep 30, 2022 | 25.25 Bn |
| Jun 30, 2022 | 27.39 Bn |
| Mar 31, 2022 | 28.69 Bn |
| Dec 31, 2021 | 28.58 Bn |
| Sep 30, 2021 | 28.52 Bn |
| Jun 30, 2021 | 29.68 Bn |